Antiangiogenics in Ophthalmology: How Rational and Ethical is the Use?

Antiangiogenics in Ophthalmology: How Rational and Ethical is the Use?

Contenido principal del artículo

Alberto Castro

Resumen

.

Detalles del artículo

Biografía del autor/a (VER)

Alberto Castro, Clinica Oftalmologica de Cali

Oftalmologo Retinologo

Referencias (VER)

Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Afl ibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-203.

Kwong TQ, Mohamed M. Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br J Clin Pharmacol 2014;78:699-706.

https://www.nice.org.uk/

Brown GC, Brown MM, Sharma S, Brown H, Smithen L, Leeser DB, Beauchamp G. Valuebased medicine and ophthalmology: an appraisal of cost-utility analyses. Trans Am Ophthalmol Soc 2004;102:177-85; discussion 185-8.

Castro A. Tendencias y costos del uso de antiangiogénicos en Colombia. Rev. Sociedad Colombiana de Oftalmología 2015;48 (3): 223 - 231.